Qiagen (QGEN) Scheduled to Post Earnings on Wednesday

Qiagen (NASDAQ:QGEN) will post its quarterly earnings results after the market closes on Wednesday, January 31st. Analysts expect Qiagen to post earnings of $0.41 per share for the quarter. Qiagen has set its Q4 guidance at $0.41-0.42 EPS.

Qiagen (NASDAQ:QGEN) last posted its earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.32. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The firm had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. During the same quarter in the prior year, the company earned $0.29 EPS. Qiagen’s revenue was up 7.5% on a year-over-year basis. On average, analysts expect Qiagen to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Qiagen (NASDAQ QGEN) opened at $33.55 on Wednesday. Qiagen has a 12 month low of $27.51 and a 12 month high of $36.34. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $7,740.00, a PE ratio of 86.03, a P/E/G ratio of 1.83 and a beta of 1.10.

Several equities analysts recently issued reports on the company. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Monday. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Friday, January 19th. BidaskClub raised Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Evercore ISI started coverage on Qiagen in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, Cowen reaffirmed a “hold” rating and issued a $34.00 price target on shares of Qiagen in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $34.63.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/24/qiagen-qgen-scheduled-to-post-earnings-on-wednesday.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Earnings History for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply